Friday, April 13, 2012
Ampio Pharmaceuticals Inc., of Greenwood Village, Colo., completed enrollment of patients in a set of clinical trials to determine the usefulness of oxidation reduction potential in hospital readmission prediction, prevention and reduction in a group of patients presenting to the emergency department with chest pain. Readmission of Medicare and Medicaid patients within 30 days of discharge costs $17 billion annually.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.